Briacell Therapeutics
BCTX
19 hedge funds and large institutions have $1.58M invested in Briacell Therapeutics in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 0 closing their positions.
4,997% more capital inflows, than outflows
Capital inflows: $374K | Capital outflows: $7.34K
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
19% more funds holding
Funds holding: 16 → 19 (+3)
0.26% more ownership
Funds ownership: 5.34% → 5.59% (+0.26%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
+$129K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$118K |
| 3 |
Jane Street
New York
|
+$97.6K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$25.1K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$3.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.32K |
| 2 |
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$18 |
BCTX Hedge Fund Activity: Q2 2026 in Review
19 of the 8,377 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q2 2026, worth a combined $1.58M — down 2.7% from $1.62M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BCTX positions and 0 closed out — a net gain of 3 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $129K. The largest seller was Morgan Stanley, cutting an estimated $7.32K.
- 19 institutional investors held Briacell Therapeutics (BCTX) as of Q2 2026, up from 16 in Q1 2026.
- Funds reported $1.58M of Briacell Therapeutics stock for Q2 2026, down 2.7% quarter-over-quarter.
- 3 funds opened new Briacell Therapeutics positions in Q2 2026 and 0 closed out, a net change of +3 holders.
- The largest Briacell Therapeutics buyer in Q2 2026 was HRT Financial, an estimated $129K added.
- The largest Briacell Therapeutics seller in Q2 2026 was Morgan Stanley, an estimated $7.32K sold.
Based on aggregated 13F filings for Q2 2026.